SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) management will be presenting a corporate overview at
an investor reception during the 43rd Annual Meeting of the European
Association for the Study of Diabetes (EASD) on Wednesday, September 19,
2007 at 4:30 a.m. PT / 1:30 p.m. CET local time in Amsterdam, Netherlands.
The live presentation will be webcast, and recordings will be made
available following the event. The webcast and recording will be accessible
through Amylin's corporate website, located at http://www.amylin.com. To
access the live webcasts, please log on to Amylin's site approximately
fifteen minutes prior to the presentation to register and download any
necessary audio software.
More information about the EASD meeting is available at:
http://www.easd.org/.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,800 employees nationwide.
Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Alice Bahner Izzo, Executive Director of
Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200, ext. 7272
|
